New $350m Site To Build Pfizer’s China Biosimilar Capacity
This article was originally published in PharmAsia News
Executive Summary
While some multinationals appear concerned about China's slowing economy and their business prospects in this market, others are forging ahead with major new investments, including Pfizer, which has just unveiled plans for a large biosimilars production and R&D site.